DexCom, Inc. vs SYSCO Corporation — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while SYSCO Corporation trades at $84.5 (market cap $40.32B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays a 2.61% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SYY | |
|---|---|---|
Market Cap | $33.79B | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $91.16 |
52-Week Low | $54.84 | $69.30 |
Enterprise Value | $33.24B | $53.50B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Sysco (SYY) trades at $84.73, up 1.03% today, with a bullish technical signal from moving averages and a consensus analyst price target of $88.25. The company reported strong Q4 2026 earnings, beating EPS estimates with $1.53 versus $1.51 expected, driven by U.S. foodservice volume growth and cost efficiencies. Revenue reached $81.37 billion in 2025, with net income of $1.83 billion, though profit margins remain thin at 2.08%. Recent news highlights CEO discussions on CNBC and operational initiatives, including AI-driven efficiencies.
The outlook for SYY is positive, supported by earnings beats, steady cash flow, and analyst optimism, but risks include competitive pressures, supply chain disruptions, and macroeconomic uncertainty. Upside potential exists if the company maintains volume growth and margin improvements, but investors should monitor debt levels and food safety issues highlighted in recent reports.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →